Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

1.130 -0.220 (-16.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 601,032
Open 1.270
Bid (Size) 1.080 (100)
Ask (Size) 1.100 (300)
Prev. Close 1.350
Today's Range 1.110 - 1.275
52wk Range 0.9500 - 52.50
Shares Outstanding 15,859,280
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Friday's session: top gainers and losers ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-08-27: top gainers and losers in today's session. ↗
Via Chartmill

Performance

YTD
-92.1%
-92.1%
1 Month
+7.6%
+7.6%
3 Month
-37.6%
-37.6%
6 Month
-75.2%
-75.2%
1 Year
-97.5%
-97.5%

More News

Read More
These stocks are the most active in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
From Propanc Biopharma, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
From Propanc Biopharma, Inc.
Via GlobeNewswire
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. ↗
Via Chartmill
These stocks are the most active in today's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
From Propanc Biopharma, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?
Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
What is the current price of Propanc Biopharma, Inc. - Common Stock?
The current price of Propanc Biopharma, Inc. - Common Stock is 1.130
When was Propanc Biopharma, Inc. - Common Stock last traded?
The last trade of Propanc Biopharma, Inc. - Common Stock was at 09/01/26 04:00 PM ET
What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
The market capitalization of Propanc Biopharma, Inc. - Common Stock is 17.92M
How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
Propanc Biopharma, Inc. - Common Stock has 18M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.